Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Osteopontin isoform c promotes the survival of cisplatin-treated NSCLC cells involving NFATc2-mediated suppression on calcium-induced ROS levels

ABSTRACT: Tumor microenvironment (TME) critically contributed to the malignant progression of transformed cells and the chemical responses to chemotherapy reagents. Osteopontin (OPN) is a secretory onco-protein with several splicing isoforms, all of which were known to regulate tumor growth and able to alter cell-cell or cell-TME communication. In this study using conditioned medium from the culture of OPNc (exon 4 excluded shorter form of OPN) overexpressing cells, we found that the survival of NSCLC cells treated with cisplatin was increased, where reduction of apoptosis by OPNc was associated with the activation of cellular calcium signals and subsequent translocation of nuclear factor of activated T cells c2 (NFATc2). The results revealed a mechanism of OPN and downstream signal for tumor cells to survive in chemo-stressed TME, which emphasized the importance of secretory proteins in alternative splicing isoforms. Our study not only demonstrated the importance of OPN neutralization for anti-tumor effects, but also implied that modulation in calcium/NFATc2/ROS axis could be a novel approach for improving the long-term outcome of NSCLC treatment.

ORGANISM(S): Homo sapiens

PROVIDER: GSE166966 | GEO | 2024/02/17

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

NFATC2 knock-down on melanoma cell line A375

Project description:RNA-seq on NFATC2 knock-down (siRNA) on melanoma cell line A375

2017-09-29 | GSE99466 | GEO

Identification of direct transcriptional targets of Nfatc2 that promote β-cell proliferation in human islets (ChIP-seq)

Project description:The transcription factor Nfatc2 is a potent β-cell mitogen in mouse and human islets, however, the direct genomic targets that mediate the mitogenic effects have not been identified. We expressed a constitutively active form of Nfatc2, and the closely related Nfatc1, in human islets and identified ~5,600 differentially expressed genes. Nfatc2 binding sites in human islets were identified via ChIP-seq, yielding ~8,600 high-confidence peaks. By integrating gene expression changes induced by Nfatc2 with genomic binding sites for Nfatc2, we identified ~2,200 direct transcriptional targets of Nfatc2 in human islets. Direct targets that were induced by Nfatc2 were enriched for transcripts that regulate the cell cycle, and for motifs associated with the transcription factor FoxP1. We showed that islets from an endocrine-specific FoxP1, FoxP2 and FoxP4 triple-knockout mouse are less responsive to Nfatc2-induced β-cell proliferation, suggesting the FoxP family may work in concert with Nfatc2 to regulate β-cell proliferation. Nfatc2 induced β-cell proliferation in both mouse and human islets, whereas Nfatc1 does so only in human islets. Exploiting this species difference in Nfatc1-responsiveness, we identified ~250 direct transcriptional targets with similar transcriptional profiles. This gene set strongly enriches for cell cycle-associated transcripts, and includes the nuclear hormone receptor, Nr4a1. We show that deletion of Nr4a1 greatly reduces the capacity of Nfatc2 to induce β-cell proliferation, suggesting that much of the effect on Nfatc2 occurs through its induction of Nr4a1. Integration of ncRNA profiling, chromatin accessibility and Nfatc2 binding sites enabled us to identify key Nfatc2-dependent enhancer loci that mediate enhanced β-cell proliferation.

2021-09-15 | GSE158496 | GEO

Identification of direct transcriptional targets of Nfatc2 that promote β-cell proliferation in human islets (ATAC-seq)

2021-09-15 | GSE158495 | GEO

Identification of direct transcriptional targets of Nfatc2 that promote β-cell proliferation in human islets (RNA-seq)

2021-09-15 | GSE158498 | GEO

Identification of direct transcriptional targets of Nfatc2 that promote β-cell proliferation in human islets (ncRNA-seq)

2021-09-15 | GSE158497 | GEO

Determining the DNA-binding targets of NFATc2 in the AML cell line THP-1

Project description:Based on previous work on the KDM histone demethylase family in AML, the transcription factor NFATC2 was identified as a regulatory target of KDM4A in MLL-AF9-rearrangement THP-1 cells. Our existing work examined the elements of the transcriptome regulated by NFATC2 in THP-1 cells and so, to further this work, we aimed to characterise the DNA-binding targets of NFATc2 in these cells. In this study, we used NFATc2 immunoprecipitation for ChIP-seq in untreated THP-1 cells, in order to determine these.

2024-09-01 | GSE241260 | GEO

RNA-Seq to identify genes regulated by NFATc2 expression in islet stress response and function

Project description:The downstream CN target NFATc2 is highest among enriched regulators of top induced genes in human islets exposed to high glucose and IL-1β. Thus, we used a conditional transgenic β-cell specific NFATc2 knock out (NFATc2βKO) mouse model to analyze requirements of NFATc2 to regulate genes in response to metabolic and inflammatory stress. Transcript analysis of NFATc2βKO islets exposed to high glucose and IL-1β revealed NFATc2-dependent downregulation of genes known to promote β-cell differentiation and upregulation of β-cell disallowed genes. Collectively, these results suggest that CN/NFATc2 signaling is required for expression of genes that maintain β cells in a differentiated state, and its inactivation allows genome-wide transcriptional changes that promote β-cell dedifferentiation when exposed to metabolic and inflammatory stress.

2022-03-01 | GSE197684 | GEO

IL-8 drives the differentiation of CD74high neutrophils to activate anti-tumor immunity and attenuate NSCLC progression [II]

Project description:Neutrophils infiltrated in the tumor microenvironment (TME) are heterogeneous populations associated with the prognosis of cancer and cancer immunotherapy. However, the plasticity and function of heterogeneous neutrophils in the TME of non-small cell lung cancer (NSCLC) remain poorly understood. Here, we show that neutrophils produce high levels of IL-8 which induce the differentiation of CD74highSiglecFlow neutrophils and suppress the generation of CD74lowSiglecFhigh neutrophils in the TME of IL-8-humanized (IL8-hu) KrasLSL-G12DTp53fl/fl (KP) and EGFRT790M/Del-Exon19 (EGFRTD) NSCLC mouse models. The CD74highSiglecFlow neutrophils exhibit antigen cross-presentation activity to augment anti-tumor T cell responses. Consistently, deletion of CD74 in IL8-hu neutrophils attenuates the activation of T cells and exacerbates the progression of NSCLC, whereas treatment of a CD74 agonist promotes anti-tumor T cell activation and enhances the effects of anti-PD1 or Osimertinib therapy in the IL8-hu NSCLC mouse models. In addition, we have found that the CD74highCD63low neutrophils in the TME and peripheral blood of advanced NSCLC patients pheno-copy the CD74highSiglecFlow neutrophils in the TME of NSCLC mice and correlate well with the responsiveness to anti-PD-1 plus chemotherapies. Collectively, these data demonstrate an IL-8-CD74high neutrophil axis that promotes anti-tumor immunity in NSCLC.

2024-09-13 | GSE252460 | GEO

IL-8 drives the differentiation of CD74high neutrophils to activate anti-tumor immunity and attenuate NSCLC progression [I]

2024-09-13 | GSE250409 | GEO

NFAT1 (NFATc2) ChIP-seq in wild-type and Mfn2-/- regenerating myofibers

Project description:We report here the genome-wide deposition of NFAT1 (NFATc2) in wild-type and Mfn2-/- regenerating myofibers.

2022-08-16 | GSE185105 | GEO